Clinical Research Directory
Browse clinical research sites, groups, and studies.
99mTc-PSMA-I&S Biodistribution in Patients With Prostate Cancer
Sponsor: Jonsson Comprehensive Cancer Center
Summary
This exploratory study conducted under the RDRC program studies the biodistribution of 99mTc-PSMA-I\&S in patients with prostate cancer who undergo pelvic lymph node dissection. Prostate specific membrane antigen (PSMA)-targeted radio-guided surgery uses the preoperative intravenous administration of a PSMA-ligand called PSMA-imaging and surgery (I\&S) labeled with the gamma-emitter radioisotope Technetium-99m (99mTc). Giving 99mTc-PSMA-I\&S may detect PSMA-expressing lymph nodes during surgery using a gamma probe and may help guide doctors to detect prostate cancer that has spread to the lymph nodes.
Official title: 99mTc-PSMA-I&Amp;S in Patients With Prostate Cancer: An Exploratory Biodistribution Study With Histopathology Validation
Key Details
Gender
MALE
Age Range
Any - Any
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2021-04-27
Completion Date
2027-06-01
Last Updated
2026-03-13
Healthy Volunteers
No
Interventions
99mTc-based PSMA Imaging and Surgery Agent
Given via IV injection
Computed Tomography
Undergo SPECT/CT
Single Photon Emission Computed Tomography
Undergo SPECT/CT
Locations (1)
UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, California, United States